Cardima Third Quarter Financial Results Call Scheduled for November 12, 2004.

FREMONT, Calif. -- Cardima, Inc. (Nasdaq SC: CRDM) will host a conference call and live webcast to discuss its third quarter financial results on Friday, November 12, 2004 at 1:30 PM Pacific Time (4:30 PM Eastern Time). Please log on to Cardima's website at www.cardima.com or call the following numbers to participate: [phone] (domestic) or [phone] (international) and use participant passcode #37746810.

William "Bill" Wheeler, Chief Operating Officer, and Barry Michaels, Chief Financial Officer, will host the call to discuss the third quarter results and to respond to investor questions. Participants are asked to call the above numbers 5-10 minutes prior to the starting time.

The Company expects to release third quarter financial results prior to the call.

A telephonic replay of this call will be available for 14 days starting from 3:30 PM Pacific Time on Friday, November 12, 2004 through 8:59 PM Pacific Time on Friday, November 26, 2004. Please call [phone] (domestic) or [phone] (international) and use participant passcode #79218277. The live webcast will be archived on Cardima's website for one year.

About Cardima

Cardima, Inc. has developed the REVELATION(R) Tx, REVELATION T-Flex and REVELATION Helix linear ablation microcatheters, the NAVIPORT deflectable guiding catheters, and the INTELLITEMP energy management system for the minimally invasive treatment of atrial fibrillation (AF). The REVELATION Helix was developed for the treatment of AF originating in the pulmonary veins of the heart. The REVELATION Tx, REVELATION T-Flex and REVELATION Helix systems and the INTELLITEMP have received CE Mark approval in Europe. The Company has also developed a Surgical Ablation System, which is expected to be used by cardiac surgeons to treat AF by ablating cardiac tissue during heart surgery using radio frequency (RF) energy. In February 2003, the Company announced that it had received FDA 510(k) clearance to market the Surgical Ablation System in the U.S.

Except for the historical information contained herein, the matters discussed in this press release, including the Company's belief about the performance and utility of its products, the Company's goals and its expectations about future trial activities and the FDA approval process, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include the risk that the Company will not be able to raise additional capital when needed to continue operations, the risk that the Company will be unable to obtain FDA approval for its pre-market approval (PMA) application for the REVELATION(R) Tx, including uncertainties associated with the Company's ability to revise its study design and collect data acceptable to the FDA, the risk that the approval process for the REVELATION Tx or any other product, including additional clinical trials, will require substantial unanticipated expenses and management attention, the limited number of cases employing the Company's products and the limited amount follow-up information involving these cases, the possibility of business disruption or unanticipated expenses due to the Company's recent staffing reduction and financing efforts, and uncertainties associated with the Company's ability to conduct successful clinical trials, obtain and maintain regulatory approvals, gain acceptance for its products from the marketplace, secure distribution partners or successfully manufacture, market, sell and distribute its products to end users in the event regulatory approvals are obtained. Additional risks are set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2003, and in the Company's Quarterly Reports on Form 10-Q for the periods ended March 31, 2004 and June 30, 2004. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.